Get In Touch
Allegory Capital SA,
Rue du Sablon 2
1110 Morges
Switzerland
+41 21 561 34 97
contact-ch@allegory.capital
Work Inquiries
work@allegory.capital
+41 21 561 34 97
  • Orsen Okami
  • Posted by Orsen Okami
June 26, 2026

A 25% Stake Can Be Worth Zero: How Liquidation Waterfalls Really Pay Out

Liquidation waterfalls pay senior preferred shareholders first, so a 25 per cent ownership stake can return nothing — ownership percentage anchors expectations that seniority quietly overrides at exit.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 26, 2026

Where April 2025 Digital Health Capital Actually Went

April 2025's biggest digital-health cheques went to diagnostics, metabolic hardware, care-operations software, and fertility infrastructure. Where value compounds next.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 25, 2026

AI Screens Deals 537× Faster, but Venture Fees Keep Climbing

An AI agent now screens early-stage deals 537 times faster than a human analyst, yet venture management fees keep rising — because the fee was never only the price of screening labour.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 23, 2026

Venture Funds Stopped Returning Cash. LPs Rewrote the Scorecard Around DPI.

Distributions to paid-in has overtaken paper marks as the number limited partners trust, and the 2017 vintage shows even strong funds returning roughly a quarter of committed capital eight years in.

Read More
A row of unbranded GLP-1 autoinjector pens on a polished steel surface in a clean pharmaceutical setting
  • Orsen Okami
  • Posted by Orsen Okami
June 23, 2026

The GLP-1 Endgame: Value Is Migrating Off the Molecule

Lilly catches Novo, Ypsomed sells diabetes care, Virta cuts GLP-1 use, WeightWatchers files Chapter 11. Where the next decade of obesity-care value sits.

Read More
Hermes harnessing a digital horse, bursting out of a computer screen showing a HERMES-AGENT terminal
  • Orsen Okami
  • Posted by Orsen Okami
June 15, 2026

Persistent-Memory Agents Are Repricing Software

Hermes, Claude Cowork and OpenClaw compared — how persistent-memory AI agents, local Llama, OpenRouter and DigitalOcean Gradient are repricing the software stack in 2026.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
June 12, 2026

Oncology's Data Gold Rush: The Asset Is the Patient Data

In 2025 pharma majors moved from buying AI to building it on someone else's data. Tempus and ConcertAI showed the asset in oncology AI is the patient data.

Read More
  • Orsen Okami
  • Posted by Orsen Okami
January 8, 2026

Neumarz Market Outlook January 2026

2026 M&A trends: why European and Swiss buyers are targeting US assets, plus outlook on healthcare, financial services, and energy consolidation.

Read More